# RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

> **NCT03908138** · PHASE4 · UNKNOWN · sponsor: **Shandong Provincial Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Hematologic Neoplasms
- Multiple Myeloma
- Efficacy
- Safety

## Interventions

- **DRUG:** RDD
- **DRUG:** VDD

## Key facts

- **NCT ID:** NCT03908138
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-30
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03908138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03908138, "RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03908138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*